Paul Perreault, CSL Behring CEO

CSL lands FDA ap­proval for he­mo­phil­ia B gene ther­a­py, sets $3.5M list price

The FDA has ap­proved the world’s first gene ther­a­py for he­mo­phil­ia B, ush­er­ing in­to the mar­ket a treat­ment that’s his­toric in both what it promis­es …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.